

Brain-Damaged Victims of Swine Flu Vaccine Win \$63 Million Lawsuit

GSK has paid out \$9.1 billion since 2003

By [Jefferey Jaxen](#)

Global Research, April 27, 2015

[Natural Society](#)

Region: [USA](#)

Theme: [Law and Justice](#), [Science and Medicine](#)

GlaxoSmithKline (GSK) is in the news again making headlines after having to settle another major lawsuit bringing the latest total to over \$9.1 billion since 2003. This time, it is due to GSK's product Pandemrix, which was the swine flu vaccine forced upon the public during the [pandemic of 2009](#) (which is argued by some to have been fake). As the victims are being compensated in the U.K., the same neurological mechanisms that damaged the children in the lawsuit are still potentially at work in the confirmed excitotoxicity that takes place after many vaccine injections.

[According to](#) the International Business Times U.K. Edition, each of the victims is “expected to receive £1 million each.” Peter Todd, a lawyer who represented many of the claimants, told the Sunday Times (U.K.):

“There has never been a case like this before. The victims of this vaccine have an incurable and lifelong condition and will require extensive medication.”

Unfortunately for Peter Todd and the countless other victims, there has been cases like this before. Neurological damage from vaccines is not a rare occurrence. In fact, the U.S. government has paid out \$3 billion and counting to families of vaccine-injured children. Most of which were due to direct neurological damage or complications arising from such damage.

According to The Corporate Research Project, the GlaxoSmithKline [rap sheet states](#):

“In recent years, GlaxoSmithKline has become known as the company that pays massive amounts to resolve wide-ranging charges brought by U.S. regulators and prosecutors.

These included a \$750 million payment relating to the sale of adulterated products from a facility in Puerto Rico and a record \$3 billion in connection with charges relating to illegal marketing, suppression of adverse safety research results and overcharging government customers. The company also set a record for the largest tax avoidance settlement with the U.S. Internal Revenue Service.”

If GlaxoSmithKline wasn't afforded legal and financial government protection status, they would have went under years ago. However, this corporate zombie still damages

populations with little oversight and deep pockets to pay for any legal or ethical challenges that get in the way.

Currently, [GlaxoSmithKline](#), [Merck](#), and other pharmaceutical houses were influential in the attempted passing of California Senate Bill 277 to remove the “parental opposition” that was slowing their product’s revenue stream. What wasn’t disclosed during the senate hearing, or vote following, was that the bill’s author Richard Pan had financial ties [to GlaxoSmithKline](#) and [Merck](#).

In a fair legal system, this should immediately disqualify the bill and bring serious moral and ethical challenges to Pan’s legitimacy. Fortunately, due to an onslaught of parents and other citizens, SB277 is currently stalled leaving Richard Pan with lots of explaining and little integrity to fall back on.

Jefferey Jaxen is an independent journalist, writer, and researcher. Focusing on personal empowerment and alternative health, his work reveals a sharp eye to capture the moment in these rapidly changing times. Jaxen is a contributing writer to NaturalSociety.com on a variety of issues. His personal page is located at [JeffereyJaxen.com](#)

The original source of this article is [Natural Society](#)
Copyright © [Jefferey Jaxen](#), [Natural Society](#), 2015

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Jefferey Jaxen](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca